Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D.
Where this comes from
- Record sourced from PubMed, PMID 32926091.
- Also identified by DOI 10.1001/jamainternmed.2020.2922 and PMC identifier 7490744.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study examines cost sharing for novel second-line diabetes treatment agents under Medicare Part D.
Medical subject headings
- Cost Sharing
- Drug Costs
- Health Expenditures
- Hypoglycemic Agents
- Medicare Part D